Sept 2002 References
References
"Choosing Surface Disinfectants," by Kathryn Dix, page 14.
1. National Institutes of Health, Division of Safety. Biologicaldecontamination: methods of disinfection. www.nih.gov/od/ors/ds/pubs/biodecontamination/biodecon1.htm.08/07/02.
2. Crawford L, Yu Z, Keegan L, Yu T. A comparison of commonly used surfacedisinfectants. Infection Control Today. November 2000, 1-9.
3. OSHA. Frequently Asked Questions: Bloodborne Pathogens. www.osha-slc.gov/html/faq-bbp.html.08/07/02.
4. Centers for Disease Control and Prevention. Sterilization or disinfectionof patient-care equipment: HIV related. www.cdc.gov/ncidod/hip/Sterile/hivsteri.htm.08/07/02.
5. Rutala WA. APIC guideline for selection and use of disinfectants. Am JInfect Control. 1996;24:313-342.
6. Rutala WA, Weber DJ. New disinfection and sterilization methods. EmergingInfect Diseases. 2001; 7(2): 348-53.
7. www.surfacine.com. 08/06/02.
Battling Biofilm: Surface Science, Antimicrobials Help Combat MedicalDevice-Related Infections," by Kelly M. Pyrek, page 32.
1. Katz J. Coating and surface treatment technology. www.devicelink.com/mddi/archive/97/04/019.html.
2. Lin TL, et al. Antimicrobial coatings: a remedy for medical device-relatedinfections. www.medicaldevicesonline.com/features/story.epml?/features.REF=47.
3. Donlan RM. Biofilms and device-related infections. www.cdc.gov/ncidod/eid/vol7no2/donlan.htm.
4. Ibid.
5. Katz J. Coating and surface treatment technology. www.devicelink.com/mddi/archive/97/04/019.html.
6. Lin TL, et al. Antimicrobial coatings: a remedy for medical device-relatedinfections. www.medicaldevicesonline.com/features/story.epml?/features.REF=47.
7. Maki DG. Infections due to infusion therapy. In: Bennett JV, Brachman PS,eds. Hospital Infections. 3rd ed. Boston: Little, Brown; 1992.
8. Plott R, Polk B, Murdock B, et al. Mortality associated with nosocomialurinary tract infection. New Engl J Med. 30(11):637-642, 1982.
9. Watson SK, Lichtenberg DA, Wainwright H. Technology vs. the most commonnosocomial infection. Infection Control Today. www.infectioncontroltoday.com/articles/081topics.html.
10. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venouscatheter-related bloodstream infection by use of an antiseptic-impregnatedcatheter. Ann Intern Med. 1997;127:267-74.
11. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, et al.Central venous catheters coated with minocycline and rifampin for the preventionof catheter-related colonization and bloodstream infections. Ann Intern Med.1997;127:267-74.
12. www.acponline.org/journals/annals/15aug97/cathedit.htm.
13. Davis RL and Etris SF. The development and functions of silver in waterpurification and disease control. The Silver Institute, Washington, D.C. www.silverfacts.org/pages/davies.html.
14. Silver-coated catheters cut infection. www.silverinstitute.org/silnews/1998/4b1998.htm.
15. Katz J. Coating and surface treatment technology. www.devicelink.com/mddi/archive/97/04/019.html
16. Rosenblatt AA and Knapp JE. Chlorine dioxide gas sterilization. HIMAConference Proceedings, pp 47-50.
"Fighting the Flu," by Susan Dolan, RN, MS, CIC, page 46
1. American Academy of Pediatrics. 2000 red book: report of the Committee onInfectious Diseases. 25th ed. Elk Grove Village, IL: American Academy ofPediatrics, 2000:351-9.
2. Bolyard EA, Tablan OC, Williams WW, et al., for the Hospital InfectionControl Practices Advisory Committee. Guideline for infection control in healthcare personnel. Am J Infect Control. 1998;26:289-354.
3. CDC. Prevention and control of influenza. Recommendations of the AdvisoryCommittee On Immunization Practices (ACIP). MMWR 2002; 51(RR03):1-31.
4. CDC. Delayed influenza vaccine availability for the 2001-02 season andsupplemental recommendations of the Advisory Committee on Immunization Practices[Notice to readers]. MMWR 2001;50:582-5.
5. Garner JS, for the Hospital Infection Control Practices AdvisoryCommittee. Guideline for isolation precautions in hospitals. Infect Control HospEpidemiol. 1996;17:53-80.
6. Hendrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment ofsymptomatic influenza A and B infection in children five to twelve years of age:a randomized controlled trial. Pediatr Infect Dis J. 2000;19:410-17.
7. MIST (Management of Influenza in the Southern Hemisphere Trialists) StudyGroup. Randomised trial of efficacy and safety of inhaled zanamivir in treatmentof influenza A and B virus infections. Lancet. 1998;352:1877-81.
8. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of theneuraminidase inhibitor zanamivir in the treatment of influenza A and B virusinfections. J Infect Dis. 1999;180:254-61.
9. Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated andcold-adapted vaccines against influenza A infection, 1985--1990: the pediatricexperience. Pediatr Infect Disease J. 2001;20:733-40.
10. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment ofinfluenza in children. Pediatr Infect Dis J. 2001;20:127-33.
11. Internet resources:
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
